Overview

Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas

Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Plitidepsin in Combination with Sorafenib or Gemcitabine in Patients with Advanced Solid Tumors or Lymphomas to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of plitidepsin in combination with sorafenib or gemcitabine in patients with advanced solid tumors or lymphomas.
Phase:
Phase 1
Details
Lead Sponsor:
PharmaMar
Treatments:
Gemcitabine
Niacinamide
Sorafenib